● pepmg Research Desk · Peer-reviewed evidence review
What the research says about dihexa
A neutral summary of the peer-reviewed literature on dihexa, an angiotensin-IV-derived peptide studied as a procognitive, synaptogenic agent in animal models. Research use only.
Preclinical only — Animal or in-vitro studies only — no controlled human trials. This describes the state of the published literature, not a claim that this compound works, is safe, or is for human use. Research use only.
The short version
- Dihexa is an orally active, brain-penetrant peptide derived from angiotensin IV, studied as a procognitive and synaptogenic (synapse-forming) agent [1][3].
- The evidence is preclinical: the cognitive findings come from rat and mouse models of memory impairment and Alzheimer's-type pathology, with mechanistic work pointing to the hepatocyte growth factor (HGF)/c-Met system [1][2].
- A systematic review of experimental (non-human) studies grouped dihexa among angiotensin-IV analogs that improved memory-task performance in animal models of cognitive deficit [5].
- This page reports what the studies measured. It is not medical advice, an efficacy or safety claim, or dosing guidance. Research use only.
What dihexa is
Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is described in the literature as a metabolically stabilized, blood-brain-barrier-permeable small molecule derived from the peptide angiotensin IV, engineered from the pre-prototype Norleucine-1-angiotensin IV to survive in the body and enter the brain when taken orally [3][6]. It was developed as a candidate procognitive/antidementia agent [6].
It is sold as a research chemical. This page summarizes the published preclinical research; material from third-party vendors is offered for laboratory and research use only and is not a medicine for any condition.
What the preclinical research has measured
Preclinical onlyThe cognitive work is in rodents. In rat models, dihexa and its parent compound reversed scopolamine-induced deficits in Morris water-maze performance and augmented hippocampal synaptogenesis, and the compound showed activity in aged-rat memory models [3]. In a mouse model of Alzheimer's-type pathology (APP/PS1), dihexa restored spatial learning, increased neuronal and synaptic markers, reduced pro-inflammatory cytokines, and acted through the PI3K/AKT signaling pathway [2].
Mechanistic studies indicate that dihexa binds with high affinity to hepatocyte growth factor (HGF) and activates its receptor c-Met; blocking that system with an HGF antagonist abolished dihexa's procognitive effect in the water-maze task, and dihexa induced hippocampal spine formation and synaptogenesis similar to HGF itself [1]. Reviews place this work within the brain renin-angiotensin system and the HGF/c-Met system as candidate targets for Alzheimer's and Parkinson's diseases [4][6].
There are no controlled human trials in this evidence base. A systematic review of experimental (non-human) studies of angiotensin-IV and related peptides found that, in models of cognitive deficit, angiotensin IV and its analogs (including dihexa) improved performance on spatial-memory and avoidance tasks in most of the studies examined [5].
What the studies report on safety and adverse events
Preclinical onlyBecause the dihexa research summarized here is preclinical, there is no controlled human safety dataset. The animal and cell studies focus on efficacy-type endpoints (memory-task performance, synapse and spine formation, receptor signaling) rather than systematic tolerability measurement in people [1][2][3].
One relevant consideration raised by the mechanistic work is that dihexa acts through the HGF/c-Met growth-factor system [1], a pathway also involved in cell growth broadly; the published studies characterize the signaling but do not provide human safety data. No adverse-event dataset in humans exists in this literature.
No human safety conclusions can be drawn from this evidence base. This is not medical advice; consult a qualified professional and read the studies directly.
How strong is the evidence
The evidence is characterized as preclinical: dihexa's procognitive and synaptogenic effects have been measured in rodent models and cell systems, with no controlled human trials in this evidence base [1][2][5]. "Preclinical" describes where the research sits, not a verdict that dihexa does or does not work in people, and results in animal cognition models frequently fail to translate.
Nothing here is dosing, medical, or safety guidance. Read the studies themselves and consult a qualified professional. This page is a map to the evidence, not a recommendation.
Sources · 6
- The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-Met system.
- AngIV-Analog Dihexa Rescues Cognitive Impairment and Recovers Memory in the APP/PS1 Mouse via the PI3K/AKT Signaling Pathway.
- Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents.
- The development of small molecule angiotensin IV analogs to treat Alzheimer's and Parkinson's diseases.
- Cognitive benefits of angiotensin IV and angiotensin-(1-7): A systematic review of experimental studies.
- The Brain Hepatocyte Growth Factor/c-Met Receptor System: A New Target for the Treatment of Alzheimer's Disease.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow any citation to its source and read it yourself. Research use only.